Unknown

Dataset Information

0

A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication.


ABSTRACT: Botulinum neurotoxins (BoNTs) are the most potent toxins to mammals. A toxoid vaccine was previously used for prevention of botulinum intoxication; however, this vaccine is no longer available. Currently, no approved botulinum vaccines are available from the Food and Drug Administration (FDA). Recently, a recombinant host cell receptor-binding subunit created for use as a potential vaccine completed phase 2 clinical trials. The current study designed a vaccine candidate against BoNT type A (BoNT/A) using a structural design. Our vaccine candidate was the BoNT/A heavy chain C-terminal region (HCR) that contained the point mutation BA15 (R1269A) within the ganglioside-binding site. A Biacore affinity test showed that the affinity of BA15 for ganglioside GT1b was 100 times lower than that of the HCR. A SNAP25 cleavage assay revealed that immunized sera blocked SNAP25 cleavage of the BoNT/A toxin via BA15. In an in vivo experiment, mice and guinea pigs immunized with BA15 produced neutralizing antibodies that protected against 3,000 LD50 of BoNT/A. In conclusion, the results of both in vitro and in vivo assays showed that our BA15 vaccine candidate was similar to the recombinant host cell receptor-binding subunit vaccine. The inability of BA15to bind ganglioside shows that BA15 is a potential safe vaccine candidate.

SUBMITTER: Yu CH 

PROVIDER: S-EPMC5806659 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication.

Yu Chi Ho CH   Song Dong Hyun DH   Choi Jun Young JY   Joe Hae Eun HE   Jeong Woo Hyeon WH   Hur Gyeung Haeng GH   Shin Young Kee YK   Jeong Seong Tae ST  

Human vaccines & immunotherapeutics 20171219 2


Botulinum neurotoxins (BoNTs) are the most potent toxins to mammals. A toxoid vaccine was previously used for prevention of botulinum intoxication; however, this vaccine is no longer available. Currently, no approved botulinum vaccines are available from the Food and Drug Administration (FDA). Recently, a recombinant host cell receptor-binding subunit created for use as a potential vaccine completed phase 2 clinical trials. The current study designed a vaccine candidate against BoNT type A (BoNT  ...[more]

Similar Datasets

| S-EPMC8352877 | biostudies-literature
| S-EPMC6825541 | biostudies-literature
| S-EPMC9324024 | biostudies-literature
| S-EPMC5021345 | biostudies-literature
| S-EPMC9764316 | biostudies-literature
| S-EPMC8223921 | biostudies-literature
| S-EPMC6180320 | biostudies-literature
| S-EPMC6748678 | biostudies-literature
| S-EPMC7925663 | biostudies-literature
| S-EPMC2593168 | biostudies-literature